Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07M | $238M | $198M | $428M | $309M | $1.18B | $1.42B | $2.46B | $3.81B | $5.34B |
| Revenue growth | — | 22179.2% | -16.8% | 116.0% | -27.9% | 280.8% | 20.4% | 73.7% | 55.0% | 40.2% |
| Gross profit | — | — | — | — | — | $1.01B | $1.13B | $2.08B | $3.22B | $4.67B |
| Gross margin | — | — | — | — | — | 86.0% | 79.8% | 84.5% | 84.4% | 87.5% |
| Operating income | -$117M | -$98.5M | -$706M | -$960M | -$1.66B | -$1.44B | -$1.79B | -$1.21B | -$568M | $447M |
| Operating margin | -10940.2% | -41.3% | -356.1% | -224.2% | -536.7% | -122.3% | -126.4% | -49.1% | -14.9% | 8.4% |
| Net income | -$119M | -$93.1M | -$674M | -$949M | -$1.62B | -$1.46B | -$2.00B | -$882M | -$645M | $287M |
| Net margin | -11141.8% | -39.1% | -339.9% | -221.5% | -526.1% | -123.9% | -141.5% | -35.9% | -16.9% | 5.4% |
| EPS (diluted) | -$0.30 | -$0.17 | -$0.93 | -$1.22 | -$1.50 | -$1.21 | -$1.49 | -$0.65 | -$0.47 | $0.19 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$89.5M | $12.8M | -$548M | -$750M | -$1.28B | -$1.30B | -$1.50B | -$1.16B | -$141M | $1.13B |
| Capital expenditures | $23.5M | $46.4M | $70.3M | $89.6M | $118M | $263M | $325M | $562M | $493M | $186M |
| Free cash flow | -$113M | -$33.6M | -$618M | -$840M | -$1.40B | -$1.56B | -$1.82B | -$1.72B | -$633M | $942M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $87.5M | $240M | $713M | $618M | $1.38B | $4.38B | $3.87B | $3.17B | $2.63B | $4.55B |
| Total assets | $406M | $1.05B | $2.25B | $1.61B | $5.60B | $8.54B | $6.38B | $5.81B | $5.92B | $8.19B |
| Total liabilities | $52.9M | $362M | $496M | $634M | $1.73B | $2.40B | $2.00B | $2.27B | $2.59B | $3.83B |
| Long-term debt | $17.3M | $9.22M | $40.8M | $83.3M | $184M | $202M | $209M | $198M | $166M | $962M |
| Shareholders' equity | $353M | $670M | $1.74B | $962M | $3.87B | $6.13B | $4.38B | $3.54B | $3.33B | $4.36B |
| Retained earnings | -$237M | -$331M | -$1.01B | -$1.96B | -$3.55B | -$5.08B | -$7.08B | -$7.96B | -$8.61B | -$8.32B |
| Shares (wtd avg diluted) | 516M | 592M | 776M | 781M | 1.09B | 1.21B | 1.34B | 1.36B | 1.37B | 1.47B |
Every figure is extracted from BeOne Medicines Ltd.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.